What Researchers Did
Researchers conducted a scoping review to investigate the potential of hyperbaric oxygen therapy (HBOT) as a complementary treatment for glioblastoma (GBM).
What They Found
They found that glioblastoma (GBM) has poor survival rates, typically ranging from 12 to 24 months, even with optimized multimodal treatment. Previous data indicated that hyperbaric oxygen therapy (HBOT) improved neoplastic tissue oxygenation, inhibited HIF-1α activity, and significantly reduced GBM cell proliferation, potentially enhancing radiotherapy outcomes with higher response rates and survival without serious adverse events.
What This Means for Canadian Patients
For Canadian patients with glioblastoma, hyperbaric oxygen therapy (HBOT) could potentially offer a new way to improve the effectiveness of standard treatments like radiation and chemotherapy. While promising, patients should discuss with their oncologists whether HBOT is a suitable option, as further research is needed to confirm its real-world benefits.
Canadian Relevance
This scoping review did not include any specific Canadian connection or data.
Study Limitations
The review highlights the need for further prospective and randomized studies to validate hyperbaric oxygen therapy's effectiveness in real-world glioblastoma clinical practice.